1. Raloxifene retards cartilage degradation and improves subchondral bone micro-architecture in ovariectomized rats with patella baja-induced - patellofemoral joint osteoarthritis
- Author
-
Ya-Ping Xiao, Liu Zhang, Zhi-Yuan Zheng, M.-J. Bei, Wen-Ya Wang, N. Liu, X.-H. Cao, Muwei Dai, Hui-Ping Song, and Faming Tian
- Subjects
Cartilage, Articular ,0301 basic medicine ,Osteoporosis ,Osteoclasts ,Cell Count ,Osteoarthritis ,Rats, Sprague-Dawley ,Patellofemoral Joint ,0302 clinical medicine ,Medicine ,Orthopedics and Sports Medicine ,Aggrecans ,Femur ,Osteoporosis, Postmenopausal ,Caspase 3 ,Patella ,Osteoarthritis, Knee ,Immunohistochemistry ,medicine.anatomical_structure ,ADAMTS4 Protein ,Ovariectomized rat ,Bone Remodeling ,medicine.drug ,Selective Estrogen Receptor Modulators ,medicine.medical_specialty ,animal structures ,Ovariectomy ,Osteocalcin ,Biomedical Engineering ,Cartilage metabolism ,Real-Time Polymerase Chain Reaction ,Bone and Bones ,Collagen Type I ,03 medical and health sciences ,Rheumatology ,Patellar Ligament ,Osteoclast ,Internal medicine ,Matrix Metalloproteinase 13 ,Animals ,Humans ,Raloxifene ,RNA, Messenger ,Collagen Type II ,Aggrecan ,030203 arthritis & rheumatology ,business.industry ,Cartilage ,X-Ray Microtomography ,medicine.disease ,Peptide Fragments ,Rats ,030104 developmental biology ,Endocrinology ,Raloxifene Hydrochloride ,business - Abstract
Summary Objective Abnormal remodeling of subchondral bone (SB) induced by estrogen deficiency has been shown to be involved in osteoarthritis (OA). Raloxifene (RAL) is commonly used to treat postmenopausal osteoporosis (OP). However, little is known about its effects on OA combined with estrogen deficiency. This study was performed to evaluate the efficacy of RAL on patella baja-induced patellofemoral joint OA (PFJOA) in an ovariectomized rat model. Design Patellar ligament shortening (PLS) and ovariectomy (OVX) were performed simultaneously in 3-month-old female Sprague–Dawley rats, which were treated with RAL (10 mg/kg/day) or vehicle at 72 h postoperatively for 10 weeks. PFJOA was assessed by immunohistochemistry (IHC), real-time polymerase chain reaction (PCR), tartrate-resistant acid phosphatase (TRAP) staining, enzyme-linked immunosorbent assay (ELISA), micro-computed tomography (μCT), histomorphology and behavioral analyses. Results X-ray examinations showed that patella baja was successfully established by PLS. Histomorphological analysis revealed that PFJOA was significantly exacerbated by OVX and markedly alleviated by RAL. Moreover, RAL improved cartilage metabolism by decreasing MMP-13, ADAMTS-4, and caspase-3 and increasing Col-II and aggrecan at both the protein and mRNA levels. Furthermore, RAL markedly improved bone mass and SB microarchitecture and reduced osteoclast numbers and the serum osteocalcin and CTX-I levels. Although RAL showed a trend toward reducing pain sensitivity based on mechanical allodynia testing, this result was not statistically significant. Conclusion These findings demonstrate that RAL treatment retards PFJOA progression in an ovariectomized rat model, suggesting that it may be a potential candidate for amelioration of the progression of PFJOA accompanied by postmenopausal OP.
- Published
- 2020